| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
H-Tyr(Me)-OH targets protein engineering and drug design applications. As a synthetic amino acid, it can be incorporated into proteins via genetic code expansion to introduce novel functionalities. It is valuable in drug design, particularly in the development of bioactive peptides for therapeutic applications in cancer, neurological disorders, and metabolic diseases. It does not have a specific biological receptor target.
|
|---|---|
| ln Vitro |
In vitro, H-Tyr(Me)-OH is used in studies involving protein interactions, receptor binding, and enzyme activity. It can be incorporated into proteins in E. coli in response to amber nonsense codons. The O-methyl group can modulate protein function and stability. It is a valuable tool in protein engineering and synthetic biology.
|
| ln Vivo |
There is limited specific in vivo activity data available for H-Tyr(Me)-OH. As a synthetic amino acid, it can be incorporated into proteins in vivo using genetic code expansion techniques. It has been studied for potential applications in drug design and therapeutic peptide development. The O-methyl group can improve peptide stability and bioavailability.
|
| Enzyme Assay |
In vitro binding assays for H-Tyr(Me)-OH involve studying its interactions with proteins and enzymes. The compound can be used in receptor binding studies to investigate the effects of O-methylation on ligand-receptor interactions. For enzyme activity studies, H-Tyr(Me)-OH can be used as a substrate or inhibitor to probe enzyme specificity. Incorporation into proteins via amber suppression allows functional studies of modified proteins.
|
| Cell Assay |
Cell culture protocols for H-Tyr(Me)-OH involve dissolving the compound in sterile water or cell culture medium. Cells (especially E. coli for protein expression) are grown in media supplemented with H-Tyr(Me)-OH for incorporation via amber suppression. Mammalian cells can be treated with the compound for studies of amino acid transport and metabolism. Concentrations typically range from 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
In vivo animal study protocols for H-Tyr(Me)-OH may involve administration via oral gavage or injection in saline. Dosing would be determined empirically based on the study objectives. Studies may assess the effects of O-methyl tyrosine incorporation on protein function, pharmacokinetics, and therapeutic efficacy. Blood and tissue samples are collected for analysis of compound distribution and protein modification.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of H-Tyr(Me)-OH are characteristic of small amino acid derivatives. The compound has a molecular weight of 195.22 g/mol, formula C₁₀H₁₃NO₃, and appears as a solid. Storage: desiccate at -20°C. Solubility: chloroform, dichloromethane, ethyl acetate, DMSO, acetone. It is expected to be absorbed following administration and distributed throughout body water compartments. Elimination is expected primarily via renal excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for H-Tyr(Me)-OH is limited. As a synthetic amino acid derivative, it is generally considered to have low acute toxicity. Standard safety precautions for handling laboratory chemicals should be observed. The compound is not intended for human therapeutic use and is classified for research purposes only. In vitro cytotoxicity studies may be performed to establish safe concentration ranges for cell-based assays.
|
| References | |
| Additional Infomation |
O-Methyl-L-tyrosine is the L-enantiomer of O-methyltyrosine. It is the enantiomer of O-methyl-D-tyrosine. It is the zwitterion tautomer of O-methyl-L-tyrosine.
H-Tyr(Me)-OH (CAS#: 6230-11-1) is also known as O-Methyl-L-tyrosine, 4-Methoxy-L-phenylalanine, and (S)-2-amino-3-(4-methoxyphenyl)propanoic acid. Its molecular formula is C₁₀H₁₃NO₃ and molecular weight is 195.22 g/mol. It is a synthetic amino acid that can be incorporated into proteins in E. coli via amber suppression and is used in drug design and protein engineering. It has no approved therapeutic indications. |
| Molecular Formula |
C10H13NO3
|
|---|---|
| Molecular Weight |
195.2151
|
| Exact Mass |
195.089
|
| CAS # |
6230-11-1
|
| PubChem CID |
2723935
|
| Appearance |
White to off-white powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
350.6±32.0 °C at 760 mmHg
|
| Melting Point |
259-261 °C (dec.)(lit.)
|
| Flash Point |
165.8±25.1 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.560
|
| LogP |
1.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
14
|
| Complexity |
188
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H]
|
| InChi Key |
GEYBMYRBIABFTA-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C10H13NO3/c1-14-8-4-2-7(3-5-8)6-9(11)10(12)13/h2-5,9H,6,11H2,1H3,(H,12,13)/t9-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(4-methoxyphenyl)propanoic acid
|
| Synonyms |
H-Tyr(Me)-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1224 mL | 25.6121 mL | 51.2243 mL | |
| 5 mM | 1.0245 mL | 5.1224 mL | 10.2449 mL | |
| 10 mM | 0.5122 mL | 2.5612 mL | 5.1224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
